Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171790
Title: | Eculizumab as a promising treatment in thymoma-associated myasthenia gravis |
Author: | Vélez Santamaria, Valentina Nedkova, Velina Díez, Laura Homedes, Christian Alberti, Maria Antonia Casasnovas Pons, Carlos |
Keywords: | Malalties autoimmunitàries Malalties neuromusculars Autoimmune diseases Neuromuscular diseases |
Issue Date: | 1-Jun-2020 |
Publisher: | Sage Publications Ltd. |
Abstract: | Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting. |
Note: | Reproducció del document publicat a: https://doi.org/10.1177/1756286420932035 |
It is part of: | Therapeutic Advances in Neurological Disorders, 2020, vol. 13 |
URI: | http://hdl.handle.net/2445/171790 |
Related resource: | https://doi.org/10.1177/1756286420932035 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1756286420932035.pdf | 232.54 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License